NASDAQ, ARQL - Arqule Inc
We are a clinical-stage biotechnology company organized as a Delaware
corporation in 1993 and engaged in the research and development of innovative
cancer therapeutics. Our mission is to introduce novel products that act
selectively against cancer cells, target multiple tumor types and are well
tolerated by patients. We believe our clinical stage products represent
potential best-in-class or first-in-class small molecule candidates based on
highly differentiated mechanisms of action.
Our lead products, which are in clinical-stage testing, consist of: ARQ 197,
an orally administered inhibitor of the c-Met receptor tyrosine kinase; ARQ 501,
an intravenously administered novel activator of the cell's DNA damage response
mechanism mediated by the E2F-1 transcription factor; and ARQ 171, an
intravenously administered second generation activator of E2F-1. ...
Read SEC Filing on NASDAQ.com »